Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run

Peyton Greenside is today’s guest on The Long Run.

Peyton Greenside, co-founder and CEO, BigHat Biosciences

Peyton is the co-founder and CEO of San Mateo, Calif.-based BigHat Biosciences. The company was started in 2019 to build on advances in synthetic biology and machine learning to design antibody drugs with a variety of different properties, faster.

The company has gone on to raise more than $100 million in venture capital and struck partnerships with a handful of large pharma companies, including AbbVie, Johnson & Johnson, Amgen, Merck, and most recently Eli Lilly.

BigHat’s drug candidates are all in preclinical development. Its focus is on cancer and inflammatory and immune disorders. Like anything else in biotech, the proof of the value of the technology platform will be determined by results from these medicines in clinical trials.

Now, please join me and Peyton Greenside on The Long Run.